Frontier Diagnostics, LLC

Smyrna, TN · Medtech · Defunct

MelanoMap™, a MALDI imaging mass spectrometry assay for melanoma diagnosis from skin biopsies

frontierdiagnostics.com →
Grants
$3.2M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
6
1 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A Molecular Diagnostic Assay for Accurately Differentiating Melanoma from Benign Lesions$299,244
Federal grantDepartment of Health and Human Services · Phase II · A Molecular Diagnostic Assay for Accurately Differentiating Melanoma from Benign Lesions$1,943,163
Federal grantDepartment of Health and Human Services · Phase II · A Molecular Diagnostic Assay for Accurately Differentiating Melanoma from Benign Lesions$944,492
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2275THERAPEUTIC BANDAGE PRODUCTS LLC——
2276CASCADE BIOSYSTEMS, INC.——
2277MASSACHUSETTS NEURO TECHNOLOGY, INC.——
2278Frontier Diagnostics, LLC——
2279GLYCODOTS, LLC——
2280GLOBAL BIOMEDICAL TECHNOLOGIES, LLC—$1.0M
2281Celldom, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 6
  • Imaging Mass Spectrometry And Uses Thereofapplication
  • Imaging Mass Spectrometry And Uses Thereofgranted
  • Mass Spectrometry Methods For Carcinoma Assessmentsapplication
  • Mass Spectrometry Methods For Carcinoma Assessmentsapplication
  • Imaging Mass Spectrometry And Uses Thereofapplication
  • Mass Spectrometry Methods For Carcinoma Assessmentsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.